Search

Your search keyword '"Roberta L. Beauchamp"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Roberta L. Beauchamp" Remove constraint Author: "Roberta L. Beauchamp"
46 results on '"Roberta L. Beauchamp"'

Search Results

2. Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations

3. Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2

4. High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy

5. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling

7. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma

8. Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2

9. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling

10. High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy

11. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK

12. Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin

13. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition

14. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma

15. CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION

16. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma

17. Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas

18. CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA

19. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas

20. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2

21. Kinome Screen Reveals SGK1 as a Therapeutic Target for NF2: Inhibition of mTORC1/2 is More Effective than Rapamycin

22. Mediator Subunit Med28 Is Essential for Mouse Peri-Implantation Development and Pluripotency

23. A NHERF binding site links the βPDGFR to the cytoskeleton and regulates cell spreading and migration

24. TorsinB - perinuclear location and association with torsinA

25. Developmental expression of the tuberous sclerosis proteins tuberin and hamartin

26. Analysis of bothTSC1 andTSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis

27. Exon scanning of the entire TSC2 gene for germline mutations in 40 unrelated patients with tuberous sclerosis

28. Analysis of Molecular Domains of Epitope-Tagged Merlin Isoforms in Cos-7 Cells and Primary Rat Schwann Cells

29. Lack of association of rare functional variants in TSC1/TSC2 genes with autism spectrum disorder

30. p53 gene analysis of ovarian borderline tumors and stage I carcinomas*1

31. The E3 ubiquitin ligase protein associated with Myc (Pam) regulates mammalian/mechanistic target of rapamycin complex 1 (mTORC1) signaling in vivo through N- and C-terminal domains

32. p53 gene mutations and protein accumulation in human ovarian cancer

33. Mediator subunit MED28 (Magicin) is a repressor of smooth muscle cell differentiation

34. Magicin associates with the Src-family kinases and is phosphorylated upon CD3 stimulation

35. Magicin (MED28), a Potential Adaptor Protein

36. Alternative splicing in protein associated with Myc (Pam) influences its binding to c-Myc

37. Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma

38. Neurofibromatosis 2 gene in human colorectal cancer

39. Pam and its ortholog highwire interact with and may negatively regulate the TSC1.TSC2 complex

40. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma

41. Detection of Heterozygous Mutation in the Retinoblastoma Gene in a Human Pituitary Adenoma Using PCR-SSCP Analysis and Direct Sequencing

42. Genetic alteratations in treatment-induced sarcomas

44. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.

45. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

46. Mediator Subunit Med28 Is Essential for Mouse Peri-Implantation Development and Pluripotency.

Catalog

Books, media, physical & digital resources